literatur
data
relev
decis
allow
waiver
vivo
bioequival
test
approv
immedi
releas
solid
oral
dosag
form
contain
ribavirin
review
ribavirin
highli
solubl
permeabl
characterist
well
defin
therefor
accord
biopharmaceut
classif
system
take
worst
case
approach
ribavirin
assign
class
iii
ribavirin
transport
across
brush
border
membran
human
jejunum
show
satur
uptak
intestin
howev
common
excipi
shown
compet
ribavirin
absorpt
problem
immedi
releas
ribavirin
formul
contain
differ
excipi
produc
differ
manufactur
method
report
open
literatur
risk
bioinequival
caus
factor
appear
low
ribavirin
consid
narrow
therapeut
index
drug
judg
compar
minimum
effect
concentr
minimum
toxic
concentr
blood
although
ribavirin
would
elig
approv
via
biopharmaceut
classif
systemebas
biowaiv
procedur
accord
today
guidanc
due
narrow
therapeut
index
risk
biowaiv
weigh
consider
risk
associ
studi
ribavirin
product
healthi
subject
literaturebas
monograph
ribavirin
concern
biopharmaceut
properti
risk
reli
vitro
test
instead
vivo
studi
result
socal
biowaiv
approv
new
immedi
releas
ir
solid
oral
dosag
form
contain
ribavirin
sole
activ
pharmaceut
ingredi
includ
reformul
product
new
multisourc
product
present
purpos
scope
seri
monograph
discuss
previous
briefli
aim
evalu
pertin
data
avail
literatur
sourc
activ
pharmaceut
ingredi
api
list
world
health
organ
list
essenti
medicin
andor
common
use
assess
risk
associ
biopharmaceut
classif
system
bc
base
biowaiv
purpos
risk
defin
combin
probabl
incorrect
biowaiv
decis
consequ
decis
term
public
health
individu
patient
risk
base
consider
monograph
assess
valid
biowaiv
recommend
accept
reject
systemat
approach
recommend
advis
biowaiv
decis
refer
guidelin
notabl
monograph
simpli
appli
variou
guidanc
biowaiverbas
eg
us
food
drug
administr
fda
medicin
agenc
ema
aim
arriv
recommend
applic
bcsbase
biowaiv
procedur
base
current
scientif
best
practic
biowaiv
monograph
alreadi
publish
varieti
api
avail
onlin
websit
intern
pharmaceut
feder
j
pharm
sci
gener
characterist
intern
nonproprietari
name
ribavirin
also
ribavirin
chemic
name
hydroxymethyl
molecular
formula
ribavirin
c
h
n
molecular
weight
gmol
ca
number
structur
ribavirin
shown
figur
ribavirin
synthet
nucleosid
analog
structur
relat
guanin
given
oral
interferon
alpha
peg
interferon
alpha
treatment
chronic
hepat
c
use
inhal
treatment
respiratori
syncyti
viru
infect
american
associ
studi
liver
diseas
guidelin
recommend
ribavirin
plu
peg
interferon
treatment
choic
chronic
hepat
c
viru
infect
evalu
clinic
outcom
patient
toler
determin
benefit
length
therapi
ribavirin
plu
peg
interferon
alfa
also
approv
fda
treatment
hepat
c
hivinfect
patient
accord
essenti
medicin
list
ribavirin
use
treatment
hepat
c
combin
peginterferon
andor
direct
act
antivir
medicin
well
treatment
viral
hemorrhag
fever
hemorrhag
fever
associ
renal
syndrom
lassa
fever
crimeancongo
hemorrhag
fever
ribavirin
also
tri
sever
acut
respiratori
syndrom
maynard
et
al
report
infect
patient
achiev
sustain
virolog
respons
svr
week
ribavirin
plasma
concentr
higher
mgml
patient
achiev
svr
week
ribavirin
concentr
lower
furthermor
aras
et
al
evalu
effect
ribavirin
concentr
week
infect
patient
svr
patient
steadyst
serum
ribavirin
concentr
mgml
patient
steadyst
serum
ribavirin
concentr
mgml
svr
ribavirin
concentr
mgml
svr
concentr
mgml
svr
report
frequenc
discontinu
therapi
serum
concentr
mgml
significantli
higher
suitabl
ribavirin
concentr
serum
week
conclud
rang
mgml
loustaudratti
et
al
investig
import
ribavirin
plasma
concentr
earli
administr
svr
infect
patient
patient
sustain
viral
respons
observ
significantli
higher
partial
area
curv
area
curv
auc
h
auc
h
record
patient
svr
could
demonstr
contrast
associ
maxim
concentr
c
max
svr
basi
result
author
propos
auc
h
cutoff
valu
mghl
common
advers
effect
report
patient
take
oral
ribavirin
combin
interferonalpha
peg
interferonalpha
central
nervou
system
reaction
anxieti
depress
irrit
insomnia
flulik
symptom
fatigu
headach
fever
rigor
advers
effect
includ
mild
lymphopenia
hyperuricemia
itch
rash
cough
nasal
stuffi
accord
american
associ
studi
liver
diseas
guidelin
hemolyt
anemia
common
side
effect
ribavirin
repres
dosedepend
side
effect
frequent
limit
ribavirin
use
maeda
et
al
show
decreas
hemoglobin
level
linearli
relat
steadyst
plasma
concentr
ribavirin
hemoglobin
level
gdl
occur
steadyst
ribavirin
concentr
increas
mgml
level
also
confirm
aras
et
al
sever
ribavirininduc
anemia
increas
fatigu
worsen
qualiti
life
henc
frequent
caus
reduct
ribavirin
dose
even
discontinu
present
physician
dilemma
efficaci
ribavirin
improv
increas
plasma
concentr
sever
anemia
also
becom
higher
increas
concentr
although
ribavirin
concentr
mgml
first
week
prevent
sever
anemia
thu
avoid
discontinu
therapi
ribavirin
concentr
mgml
week
therapi
improv
svr
infect
patient
signific
reduct
hemoglobin
observ
dose
ribavirin
reduc
soon
possibl
make
safe
continu
therapi
possibl
reduc
incid
discontinu
advers
effect
potenti
lifethreaten
fatal
includ
sever
depress
suicid
ideat
relaps
drug
abus
overdos
eg
narcot
bacteri
infect
comprehens
list
report
advers
effect
avail
literatur
ribavirin
metabolit
clear
kidney
drug
use
extrem
caution
patient
renal
diseas
renal
failur
also
avoid
patient
sever
hepat
impair
decompens
cirrhosi
liver
childpugh
class
b
c
acut
ingest
g
rebetol
capsul
associ
increas
incid
sever
usual
advers
effect
drug
ribavirin
accumul
human
erythrocyt
remain
bodi
week
longer
administr
drug
hemodialysi
periton
dialysi
effect
treatment
ribavirin
overdosag
hypocalcemia
hypomagnesemia
also
observ
person
administ
greater
recommend
dose
ribavirin
case
ribavirin
administ
intraven
dose
case
exceed
time
recommend
maximum
oral
daili
dose
ribavirin
describ
freeli
solubl
water
differ
pharmacopoeia
c
maximum
aqueou
solubl
valu
ribavirin
report
mgml
zhao
et
al
calcul
aqueou
solubl
mgml
use
wskow
window
william
meylan
calcul
dose
solubl
ml
water
dosag
form
contain
mg
ribavirin
highest
strength
ribavirin
global
market
show
dose
dissolv
complet
dose
solubl
ratio
differ
ph
fulli
discuss
literatur
howev
one
report
indic
solubl
ribavirin
gener
product
test
buffer
solut
physiolog
ph
rang
found
high
case
ribavirin
contain
four
chiral
center
sugar
portion
molecul
thu
possibl
stereoisom
ribavirin
synthes
singl
isom
use
enantiomer
pure
form
ribavirin
addit
show
polymorph
polymorph
form
b
distinguish
melt
rang
one
form
crystal
aqueou
ethanol
melt
c
c
form
form
b
crystal
ethanol
melt
rang
c
knowledg
author
clearli
mention
literatur
polymorph
use
market
product
refer
literatur
discuss
whether
polymorph
form
affect
physicochem
properti
bioavail
ba
clinic
efficaci
ribavirin
howev
suggest
high
solubl
ribavirin
limit
risk
polymorph
effect
ribavirin
polar
compound
calcul
zhao
et
al
use
clogp
window
softwar
biobyt
version
claremont
ca
result
valu
logarithm
octanolwat
partit
coeffici
clogp
anoth
work
experiment
log
p
mlogp
report
pka
ribavirin
ampholyt
acid
basic
group
pka
valu
report
literatur
acid
base
respect
valu
indic
physiolog
relev
ph
valu
compound
uncharg
list
essenti
medicin
list
mg
ribavirin
solid
dosag
form
treatment
viral
hemorrhag
fever
unit
state
us
europ
ribavirin
market
mg
oral
solid
dosag
form
shown
tabl
list
ir
ribavirin
tablet
capsul
market
author
ma
belgium
canada
czech
republ
germani
denmark
spain
european
union
eu
finland
franc
hungari
ireland
iceland
netherland
norway
portug
romania
sweden
slovakia
unit
kingdom
unit
state
ribavirin
typic
administ
oral
dose
mg
twice
daili
ribavirin
rapidli
absorb
circul
uptak
mechan
activ
transport
human
concentr
nucleosid
transport
proxim
small
bowel
satur
uptak
ribavirin
human
intestin
like
explan
observ
high
dose
mg
maxim
plasma
concentr
ribavirin
oral
administr
drug
increas
proport
dose
studi
run
human
determin
absorpt
absolut
ba
ribavirin
six
healthi
volunt
receiv
mg
intraven
c
ribavirin
follow
h
later
oral
dose
ribavirin
studi
oral
administ
drug
found
absorb
although
mean
absolut
ba
dose
ribavirin
found
low
oral
ba
thought
caus
least
part
firstpass
metabol
pharmacokinet
paramet
ribavirin
posit
influenc
food
manufactur
ribavirin
capsul
rebetol
tablet
copegu
refer
list
drug
product
avail
sever
market
recommend
drug
product
taken
food
given
administr
fed
state
increas
c
max
auc
max
permeabl
inform
permeabl
ribavirin
literatur
limit
cell
appar
permeabl
ribavirin
report
cm
mention
high
permeabl
control
drug
use
studi
low
permeabl
ribavirin
cell
monolay
probabl
due
lack
high
express
transport
system
ribavirin
minim
bound
plasma
protein
transport
cell
member
equilibr
nucleosid
transport
famili
wide
present
volum
distribut
high
sever
thousand
liter
transport
nonplasma
compart
mainli
studi
red
cell
ratio
distribut
among
whole
blood
plasma
follow
singl
oral
dose
plasma
concentr
ribavirin
exhibit
threephas
profileda
rapid
absorpt
phase
follow
rapid
distribut
phase
longtermin
elimin
phase
halflif
distribut
phase
h
termin
elimin
phase
long
mean
final
concentr
time
point
follow
singl
dose
h
elimin
halflif
h
c
max
auc
obey
linear
relationship
dosag
usual
dose
rang
mg
although
higher
dose
mg
c
max
show
nonlinear
increas
follow
multipl
dose
ribavirin
gradual
accumul
plasma
reach
maximum
concentr
c
ss
max
week
mean
c
ss
max
follow
multipl
dose
mg
indic
nearli
increas
c
max
follow
singl
dose
remark
termin
elimin
phase
elong
follow
multipl
dose
mean
halflif
rang
h
ribavirin
detect
week
cessat
administr
ribavirin
elimin
metabol
well
renal
elimin
latter
account
parent
drug
elimin
follow
singl
dose
administr
thu
metabol
play
key
role
ribavirin
elimin
ribavirin
ca
cz
de
dk
es
eu
fr
hu
metabol
two
differ
pathway
phosphoryl
pathway
revers
result
activ
metabolit
ribavirin
triphosph
degrad
pathway
via
deribosyl
hydrolysi
amid
group
pharmacokinet
profil
ribavirin
remain
unchang
hepat
dysfunct
suggest
liver
major
site
ribavirin
metabol
gastrointestin
tract
liver
thu
appear
major
site
firstpass
elimin
possibl
competit
firstpass
metabol
food
compon
account
least
part
observ
posit
food
effect
vivo
studi
compar
gener
drug
product
filmcoat
tablet
hard
capsul
mg
origin
drug
product
name
rebetol
mg
hard
gelatin
capsul
identifi
three
differ
multisourc
product
eu
market
detail
studi
present
tabl
detail
composit
formul
use
studi
disclos
case
compar
gener
formul
bioequival
studi
perform
openlabel
random
twoperiod
crossov
studi
day
washout
period
conduct
biopartn
gmbh
male
healthi
volunt
receiv
singl
dose
filmcoat
tablet
versu
rebetol
hard
capsul
first
studi
enrol
subject
complet
studi
second
one
enrol
subject
complet
studi
product
administr
fed
fast
condit
respect
c
max
auc
met
standard
criteria
bioequival
anoth
evalu
gener
ribavirin
hard
capsul
teva
pharmaceut
industri
ltd
refer
product
demonstr
random
parallel
arm
studi
male
individu
receiv
singl
dose
fed
state
condit
confid
interv
ratio
geometr
mean
c
max
auc
within
limit
studi
conduct
fast
volunt
complet
fed
volunt
complet
condit
openlabel
twoway
crossov
studi
least
washout
period
three
river
pharmaceut
llc
healthi
volunt
receiv
singl
dose
capsul
versu
origin
counterpart
result
show
point
estim
confid
interv
first
studi
auc
c
max
second
studi
auc
c
max
fell
within
usual
bioequival
accept
rang
two
random
openlabel
twoway
crossov
studi
fast
condit
healthi
femal
subject
compani
demonstr
gener
product
bioequival
rebetol
hard
gelatin
capsul
howev
pk
paramet
studi
made
avail
open
literatur
anoth
report
bioequival
singledos
russian
ribavirin
oral
dosag
form
versu
singledos
rebetol
compar
studi
product
prove
bioequival
bioinequival
origin
product
gener
report
date
may
reflect
report
bia
studi
publish
open
literatur
excipi
present
ir
ribavirin
tablet
capsul
belgium
canada
czech
republ
germani
denmark
spain
eu
openlabel
random
twoperiod
crossov
studi
day
washout
period
fed
condit
b
openlabel
random
twoperiod
crossov
studi
day
washout
period
fast
condit
c
random
parallel
fed
condit
openlabel
twoperiod
twotreat
twosequ
twoway
crossov
studi
least
washout
period
fast
condit
e
openlabel
twoperiod
twotreat
twosequ
twoway
crossov
studi
least
washout
period
fed
condit
f
random
openlabel
twotreat
crossov
studi
fast
condit
g
random
openlabel
twotreat
crossov
studi
fed
condit
finland
franc
hungari
ireland
iceland
netherland
norway
portug
romania
sweden
slovakia
unit
kingdom
unit
state
present
tabl
even
though
mani
product
market
number
excipi
due
satur
uptak
across
jejunum
purinelik
excipi
potenti
influenc
ribavirin
ba
howev
none
excipi
list
tabl
purinelik
structur
although
product
polyethylenglycol
mannitol
caus
osmot
effect
therefor
potenti
reduc
absorpt
highli
permeabl
drug
substanc
effect
detect
dissolut
test
product
pass
vivo
bioequival
criteria
excess
amount
anoth
excipi
magnesium
stearat
could
hinder
dissolut
pick
biowaiv
dissolut
test
similarli
lack
problem
ir
formul
contain
differ
excipi
case
bioinequival
ribavirin
product
due
differ
manufactur
process
report
open
literatur
current
usp
monograph
dissolut
condit
specif
ribavirin
tablet
describ
less
q
dissolv
min
ml
water
use
paddl
apparatu
rpm
similarli
dissolut
condit
specif
ribavirin
capsul
describ
less
q
dissolv
min
ml
water
use
basket
apparatu
rpm
method
suggest
fda
ribavirin
capsul
tablet
present
tabl
two
vivo
studi
describ
section
bioequival
studi
also
compar
dissolut
innov
gener
drug
product
find
similar
qualit
composit
ribavirin
biopartn
baar
switzerland
new
gener
product
differ
rebetol
refer
product
gener
product
pharmaceut
form
filmcoat
tablet
refer
product
pharmaceut
form
hard
capsul
author
knowledg
comparison
product
use
bcsbase
biowaiv
method
publish
date
open
literatur
solubl
criteria
defin
present
regulatori
guidanc
classifi
api
highli
solubl
requir
highest
dosag
strength
solubl
c
ml
aqueou
solut
ph
rang
accord
eu
guidanc
accord
fda
guidanc
solubl
studi
literatur
complet
cover
condit
although
assess
report
ema
indic
ribavirin
solubl
evalu
ph
rang
found
high
within
rang
base
avail
solubl
dose
inform
take
pka
valu
account
ribavirin
consid
highli
solubl
fda
defin
highli
permeabl
fraction
dose
absorb
ema
guidanc
guidelin
set
limit
fraction
dose
absorb
inform
permeabl
ribavirin
literatur
limit
one
hand
absolut
ba
rang
like
least
partli
due
firstpass
metabol
report
suggest
oral
administ
drug
absorb
would
put
ribavirin
borderlin
highli
highli
permeabl
context
ema
regul
would
fail
meet
current
fda
requir
highli
permeabl
low
permeabl
ribavirin
cell
monolay
probabl
due
lack
high
express
transport
system
therefor
particularli
help
term
classifi
permeabl
drug
exist
data
inconclus
ribavirin
conserv
classifi
highli
permeabl
purpos
biowaiv
combin
solubl
permeabl
data
discuss
ribavirin
conserv
classifi
belong
bc
class
iii
highli
solubl
highest
dose
strength
highest
singl
dose
recommend
prescrib
inform
highest
recommend
oral
dose
ribavirin
chronic
hepat
c
patient
kg
weight
mg
morn
mg
even
best
borderlin
permeabl
valu
public
takagi
et
al
support
classif
report
bioinequival
ir
oral
product
contain
ribavirin
open
literatur
howev
possibl
bioequival
result
report
open
literatur
date
discount
complet
data
set
avail
evalu
predict
power
vitro
dissolut
approach
compar
dissolut
test
three
media
prescrib
bcsbase
biowaiv
although
differ
excipi
formul
seem
lead
bioinequival
role
intestin
transport
ribavirin
absorpt
purinelik
excipi
theoret
potenti
influenc
ribavirin
ba
howev
excipi
characterist
found
product
list
tabl
although
excipi
list
tabl
potenti
interact
gastrointestin
absorpt
gener
way
includ
excipi
influenc
lumin
osmol
risk
interact
appear
low
drug
product
excipi
exist
intern
confer
harmon
associ
countri
assum
vivo
studi
success
pass
product
one
viewpoint
express
valid
methodolog
predict
effect
formul
compon
transport
develop
expans
biowaiv
drug
absorb
mechan
riski
howev
sinc
greater
amount
inform
topic
becom
avail
lead
opinion
mani
bc
class
iii
drug
product
fact
elig
biowaiv
consider
specif
excipi
present
drug
product
concept
approv
product
contain
bc
class
iii
drug
biowaiv
endors
guidanc
ema
well
consensu
paper
pharmaceut
scienc
confer
current
consider
fda
mention
therapeut
index
toxic
section
higher
concentr
ribavirin
higher
efficaci
observ
higher
concentr
also
associ
increas
sever
anemia
frequent
side
effect
ribavirin
subbioequival
product
may
lack
efficaci
may
result
svr
hand
suprabioequival
product
may
give
rais
greater
probabl
sever
anemia
recogn
sever
advers
effect
ribavirin
safeti
concern
associ
potenti
suprabalik
hypocalcemia
hypomagnesemia
less
concern
unwant
effect
observ
dose
much
greater
recommend
dose
ribavirin
minimum
effect
concentr
need
attain
accept
svr
agre
sever
report
literatur
mgml
concentr
anemia
occur
report
mgml
state
cfr
c
drug
product
exhibit
less
differ
minimum
toxic
concentr
minimum
effect
concentr
blood
consid
narrow
therapeut
ratio
comparison
concentr
need
accept
therapi
minimum
concentr
hemolyt
anemia
observ
report
open
literatur
lead
conclus
narrow
therapeut
window
ribavirin
drug
regard
narrow
therapeut
index
ethic
aspect
associ
conduct
bioequival
studi
human
must
balanc
risk
associ
implement
bcsbase
biowaiv
case
ribavirin
ethic
aspect
confound
high
variabl
pk
among
subject
given
fast
state
lead
necess
enrol
larg
number
subject
order
adequ
assess
equival
product
within
jurisdict
util
averag
scale
bioequival
yet
establish
furthermor
seem
high
initi
dose
case
singl
dose
like
result
advers
effect
address
issu
option
avail
first
would
test
equival
lower
dose
healthi
volunt
eg
mg
fed
state
would
reduc
risk
individu
subject
well
reduc
variabl
data
cv
fast
state
versu
fed
state
ii
second
would
enrol
patient
equival
studi
although
also
rais
question
whether
therapi
would
compromis
case
test
product
equival
refer
product
iii
third
option
would
consid
appli
bcsbase
biowaiv
even
though
ribavirin
nti
substanc
case
caution
taken
regard
criteria
vitro
dissolut
similar
excipi
composit
r
formul
earli
drug
exposur
first
dose
h
report
critic
attain
svr
base
avail
evid
ribavirin
classifi
bc
class
iii
drug
high
solubl
borderlin
permeabl
valu
addit
class
api
guidelin
ema
guidelin
extend
possibl
biowaiv
approv
bc
class
iii
api
certain
condit
howev
ribavirin
discuss
consid
nti
drug
less
differ
minimum
toxic
concentr
minimum
effect
concentr
blood
hemolyt
anemia
frequent
sever
side
effect
ribavirin
limit
therapi
substanc
sever
anemia
increas
increas
ribavirin
plasma
concentr
give
rise
patient
risk
either
subbioequival
suprabioequival
product
therefor
even
though
ribavirin
bc
class
iii
drug
report
product
bioinequival
literatur
biowaiv
ir
ribavirin
solid
oral
dosag
form
would
consid
accept
accord
current
bioequival
guidanc
narrow
therapeut
index
although
bioequival
new
solid
oral
dosag
form
contain
ribavirin
principl
approv
basi
pharmacokinet
studi
regulatori
author
may
wish
determin
best
option
assess
bioequival
ribavirin
product
context
local
need
